Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Harmony Biosciences to replace Retail Properties of America in S&P 600 on 10/22  04:55
10/22/21
10/22
04:55
10/22/21
04:55
HRMY

Harmony Biosciences

$40.71 /

-1.29 (-3.07%)

, RPAI

Retail Properties of America

$13.18 /

-0.41 (-3.02%)

 
ShowHide Related Items >><<
RPAI Retail Properties of America
$13.18 /

-0.41 (-3.02%)

HRMY Harmony Biosciences
$40.71 /

-1.29 (-3.07%)

HRMY Harmony Biosciences
$40.71 /

-1.29 (-3.07%)

10/06/21 Jefferies
Takeda news positive for Harmony Biosciences, says Jefferies
09/22/21 Needham
Harmony Biosciences initiated with a Buy at Needham
03/29/21 Goldman Sachs
Harmony Biosciences upgraded to Buy from Neutral at Goldman Sachs
RPAI Retail Properties of America
$13.18 /

-0.41 (-3.02%)

06/08/21 Deutsche Bank
Retail Properties of America price target raised to $14 from $12 at Deutsche Bank
04/15/21 Deutsche Bank
Retail Properties of America price target raised to $12 from $10 at Deutsche Bank
04/14/21 Baird
Retail Properties of America assumed with a Neutral at Baird
04/13/21 Baird
Retail Properties of America reinstated with a Neutral at Baird
RPAI Retail Properties of America
$13.18 /

-0.41 (-3.02%)

HRMY Harmony Biosciences
$40.71 /

-1.29 (-3.07%)

HRMY Harmony Biosciences
$40.71 /

-1.29 (-3.07%)

Thursday
Recommendations
Seelos shares offer 'significant potential upside optionality,' says B. Riley » 09:52
10/21/21
10/21
09:52
10/21/21
09:52
SEEL

Seelos Therapeutics

$2.22 /

+ (+0.00%)

, SAGE

Sage Therapeutics

$40.92 /

+0.15 (+0.37%)

B. Riley analyst Mayank…

B. Riley analyst Mayank Mamtani calls Seelos Therapeutics (SEEL) his top "Battered Bastions" pick with the stock down 60% from intra-year highs. The company's fundamentals have strengthened as it pertains to the competitive positioning of its two lead pivotal-stage candidates, SLS-002 for the treatment of acute suicide ideation and behavior in patients with major depressive disorder and trehalose in patients with amyotrophic lateral sclerosis, Mamtani tells investors in a research note. The analyst is "encouraged" by the cross-read from Sage Therapeutics' (SAGE) recent regulatory strategy update of zuranolone in major depressive disorder to SLS-002's indication expansion plans in a larger prevalence, chronic disease setting. Also noteworthy is Seelos's progress with gene therapy candidate SLS-004, in which positive data in an in-vivo rat model utilizing CRISPR-dCas9 demonstrated that a single dose of SLS-004 reduced alpha-synuclein mRNA by 27% and SNCA protein expression by 40%, says the analyst. He sees "significant potential upside optionality" to the firm's $11 price target and reiterates a Buy rating on the shares.

ShowHide Related Items >><<
SEEL Seelos Therapeutics
$2.22 /

+ (+0.00%)

SAGE Sage Therapeutics
$40.92 /

+0.15 (+0.37%)

SEEL Seelos Therapeutics
$2.22 /

+ (+0.00%)

09/27/21 Roth Capital
Seelos Therapeutics upgraded to Buy from Neutral at Roth Capital
08/18/21 B. Riley
Seelos Therapeutics price target lowered to $11 from $15 at B. Riley
07/06/21 Benchmark
Seelos patient dosing a positive for the stock, says Benchmark
07/01/21 Guggenheim
Seelos Therapeutics initiated with a Buy at Guggenheim
SAGE Sage Therapeutics
$40.92 /

+0.15 (+0.37%)

10/20/21 Oppenheimer
Sage Therapeutics price target lowered to $84 from $100 at Oppenheimer
10/19/21 Morgan Stanley
Sage Therapeutics assumed with an Equal Weight at Morgan Stanley
10/06/21 Jefferies
Sage Therapeutics downgraded to Hold from Buy at Jefferies
10/06/21 Jefferies
Sage Therapeutics assumed with Hold from Buy at Jefferies
SAGE Sage Therapeutics
$40.92 /

+0.15 (+0.37%)

  • 20
    May
  • 20
    Apr
  • 26
    Jan
SAGE Sage Therapeutics
$40.92 /

+0.15 (+0.37%)

Wednesday
Earnings
Rexford Industrial sees FY21 core FFO $1.60-1.61, consensus $1.56  16:19
10/20/21
10/20
16:19
10/20/21
16:19
REXR

Rexford Industrial

$63.80 /

+1.48 (+2.37%)

 
ShowHide Related Items >><<
REXR Rexford Industrial
$63.80 /

+1.48 (+2.37%)

REXR Rexford Industrial
$63.80 /

+1.48 (+2.37%)

08/10/21 Wells Fargo
Rexford Industrial price target raised to $65 from $58 at Wells Fargo
07/19/21 Capital One
Rexford Industrial upgraded to Overweight from Equalweight at Capital One
06/07/21 Wells Fargo
Rexford Industrial price target raised to $58 from $51 at Wells Fargo
10/28/20 Berenberg
Rexford Industrial initiated with a Buy at Berenberg
REXR Rexford Industrial
$63.80 /

+1.48 (+2.37%)

  • 23
    Sep
  • 25
    May
  • 02
    Dec
REXR Rexford Industrial
$63.80 /

+1.48 (+2.37%)

Earnings
Rexford Industrial reports Q3 core FFO 43c, consensus 39c » 16:18
10/20/21
10/20
16:18
10/20/21
16:18
REXR

Rexford Industrial

$63.80 /

+1.48 (+2.37%)

Reports Q3 revenue…

Reports Q3 revenue $115.4M, consensus $109.5M.

ShowHide Related Items >><<
REXR Rexford Industrial
$63.80 /

+1.48 (+2.37%)

REXR Rexford Industrial
$63.80 /

+1.48 (+2.37%)

08/10/21 Wells Fargo
Rexford Industrial price target raised to $65 from $58 at Wells Fargo
07/19/21 Capital One
Rexford Industrial upgraded to Overweight from Equalweight at Capital One
06/07/21 Wells Fargo
Rexford Industrial price target raised to $58 from $51 at Wells Fargo
10/28/20 Berenberg
Rexford Industrial initiated with a Buy at Berenberg
REXR Rexford Industrial
$63.80 /

+1.48 (+2.37%)

  • 23
    Sep
  • 25
    May
  • 02
    Dec
REXR Rexford Industrial
$63.80 /

+1.48 (+2.37%)

Conference/Events
Steelcase management to meet virtually with Benchmark » 14:27
10/20/21
10/20
14:27
10/20/21
14:27
SCS

Steelcase

$12.76 /

+0.19 (+1.51%)

Virtual Meetings to be…

Virtual Meetings to be held on October 27-28 hosted by Benchmark.

ShowHide Related Items >><<
SCS Steelcase
$12.76 /

+0.19 (+1.51%)

SCS Steelcase
$12.76 /

+0.19 (+1.51%)

05/11/21 Berenberg
Berenberg starts 'market leader' Steelcase at Buy
05/11/21 Berenberg
Steelcase initiated with a Buy at Berenberg
05/07/21 Benchmark
Benchmark upgrades Steelcase to Buy on signs of recovery in commercial furniture
05/07/21 Benchmark
Steelcase upgraded to Buy from Hold at Benchmark
SCS Steelcase
$12.76 /

+0.19 (+1.51%)

SCS Steelcase
$12.76 /

+0.19 (+1.51%)

SCS Steelcase
$12.76 /

+0.19 (+1.51%)

Hot Stocks
Medirom Healthcare reports 316 salons in September » 08:22
10/20/21
10/20
08:22
10/20/21
08:22
MRM

Medirom Healthcare

$7.68 /

-0.14 (-1.79%)

MEDIROM Healthcare…

MEDIROM Healthcare Technologies announced its major Key Performance Indicators, or KPIs, updated for the month of September 2021.The following monthly KPIs provide insight into the business fundamentals and progress of the Company, updated for the month of September 2021. The number of salons was 316 in September 2021, up from 284 in the year-ago period, primarily as a result of the acquisition of another brand in May 2021. Total customers served were 65,130 in September 2021, almost no change from September 2020. Sales per customer increased to JPY 6,428 in September 2021, up from JPY6,245 in September 2020. The increase is attributed to the upselling of value-added optional services. Our repeat ratio, a measure of repeat customers, was 82.0% in September 2021, almost no change from September 2020. Our operation ratio was 46.7% in September 2021, decreasing from 48.1% in the year-ago period. Total number of salons with data was 221 in September 2021, no change from September 2020. The number of salons with data decreases when we close salons with data available and increases as we open salons with such data.

ShowHide Related Items >><<
MRM Medirom Healthcare
$7.68 /

-0.14 (-1.79%)

MRM Medirom Healthcare
$7.68 /

-0.14 (-1.79%)

  • 29
    Dec
MRM Medirom Healthcare
$7.68 /

-0.14 (-1.79%)

Recommendations
Sage Therapeutics price target lowered to $84 from $100 at Oppenheimer » 08:10
10/20/21
10/20
08:10
10/20/21
08:10
SAGE

Sage Therapeutics

$40.27 /

-3.78 (-8.58%)

Oppenheimer analyst Jay…

Oppenheimer analyst Jay Olson lowered the firm's price target on Sage Therapeutics to $84 from $100 and keeps an Outperform rating on the shares. The analyst notes Sage shares were pressured by plans to complete zuranolone's NDA for MDD in the second half of 2022 with rolling submission beginning early-2022. Following a pre-NDA meeting, Sage clarified that positive Phase 3 WATERFALL efficacy results plus existing datasets, including Phase 3 SHORELINE and MOUNTAIN, are sufficient to begin the rolling submission process, and the company plans to include Phase 3 CORAL data once available in early-2022.

ShowHide Related Items >><<
SAGE Sage Therapeutics
$40.27 /

-3.78 (-8.58%)

SAGE Sage Therapeutics
$40.27 /

-3.78 (-8.58%)

10/19/21 Morgan Stanley
Sage Therapeutics assumed with an Equal Weight at Morgan Stanley
10/06/21 Jefferies
Sage Therapeutics downgraded to Hold from Buy at Jefferies
10/06/21 Jefferies
Sage Therapeutics assumed with Hold from Buy at Jefferies
10/04/21 Piper Sandler
Profile of Sage's zuranolone sufficient for NDA filing, says Piper Sandler
SAGE Sage Therapeutics
$40.27 /

-3.78 (-8.58%)

SAGE Sage Therapeutics
$40.27 /

-3.78 (-8.58%)

Tuesday
Options
BlackBerry call volume above normal and directionally bullish » 13:45
10/19/21
10/19
13:45
10/19/21
13:45
BB

BlackBerry

$10.85 /

+0.74 (+7.32%)

Bullish option flow…

Bullish option flow detected in BlackBerry with 101,293 calls trading, 1.7x expected, and implied vol increasing almost 6 points to 68.67%. 10/22 weekly 11 calls and 10/22 weekly 10.5 calls are the most active options, with total volume in those strikes near 36,000 contracts. The Put/Call Ratio is 0.15. Earnings are expected on December 21st.

ShowHide Related Items >><<
BB BlackBerry
$10.85 /

+0.74 (+7.32%)

BB BlackBerry
$10.85 /

+0.74 (+7.32%)

09/23/21 TD Securities
TD keeps Reduce rating on BlackBerry, calls Q2 beat 'low-quality'
09/23/21 RBC Capital
BlackBerry patents sale price to have material impact on stock, says RBC Capital
08/18/21
Fly Intel: Top five analyst upgrades
08/18/21 Canaccord
BlackBerry upgraded to Hold from Sell at Canaccord
BB BlackBerry
$10.85 /

+0.74 (+7.32%)

BB BlackBerry
$10.85 /

+0.74 (+7.32%)

BB BlackBerry
$10.85 /

+0.74 (+7.32%)

BB BlackBerry
$10.85 /

+0.74 (+7.32%)

Hot Stocks
Avadel Pharmaceuticals presents new data from Phase 3 REST-ON trial of FT218 » 08:22
10/19/21
10/19
08:22
10/19/21
08:22
AVDL

Avadel Pharmaceuticals

$8.47 /

-1.51 (-15.14%)

Avadel Pharmaceuticals…

Avadel Pharmaceuticals announced new data from the completed pivotal Phase 3 REST-ON clinical trial of FT218, also known as ON-SXB. The post-hoc data are being presented in as two separate posters at the American College of Chest Physicians annual meeting, taking place virtually October 17 - 20, 2021, along with the results of a discrete choice experiment to understand patient preference. FT218 is the Company's lead drug candidate, an investigational formulation of sodium oxybate designed to be taken once at bedtime for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. FT218 is currently under review at the U.S. Food and Drug Administration. Sleep Latency Response with FT218, a Once-Nightly Sodium Oxybate: Post-Hoc Responder Analyses from the Phase 3 REST-ON Clinical Trial. ON-SXB treatment was associated with statistically significant improvements compared to placebo on mean sleep latency in the Phase 3 REST-ON clinical trial: a significantly greater proportion of participants who received ON-SXB compared to placebo experienced increased mean sleep latency change from baseline. Improvement was evident as early as week 3 at the 6-g dose and increased with the 7.5-g dose at week 8 and the 9-g dose at week 13. The most common adverse drug reactions with ON-SXB 9 g were enuresis, dizziness, and vomiting. Cataplexy Response with FT218, a Once-Nightly Sodium Oxybate: Post-Hoc Responder Analyses from the Phase 3 REST-ON Clinical Trial. ON-SXB treatment was associated with statistically significant improvements compared to placebo on the number of weekly cataplexy episodes, as shown by the results of the pivotal Phase 3 REST-ON clinical trial: A significantly greater proportion of participants treated with ON-SXB compared to placebo experienced 25%, 50% and 75% reductions in the number of weekly cataplexy episodes with once-at-bedtime doses of 6, 7.5, and 9 g. Of participants taking the two highest doses of ON-SXB, approximately 10% had complete elimination of their cataplexy, while approximately half had a 50% reduction and one-third had a 75% reduction in their weekly cataplexy episodes. The most common adverse drug reactions with ON-SXB 9 g were enuresis, dizziness, and vomiting. The Utility of Discrete Choice Experiment in Evaluating Treatment Preferences Among Patients with Narcolepsy. A discrete choice experiment evaluated drivers of patient preference for sodium oxybate and demonstrated that dosing frequency was the single most important attribute of a narcolepsy treatment, with once-nightly dosing significantly more preferred than twice-nightly dosing. The number of nightly doses was also the most important driver observed of "taking the medication exactly as directed" and "reduced anxiety/stress", with once-nightly dosing preferred over twice-nightly dosing.

ShowHide Related Items >><<
AVDL Avadel Pharmaceuticals
$8.47 /

-1.51 (-15.14%)

AVDL Avadel Pharmaceuticals
$8.47 /

-1.51 (-15.14%)

09/22/21 Needham
Avadel Pharmaceuticals initiated with a Buy at Needham
08/10/21 H.C. Wainwright
Avadel Pharmaceuticals approvability concerns 'overblown,' says H.C. Wainwright
03/10/21 H.C. Wainwright
Avadel Pharmaceuticals price target raised to $17 from $15 at H.C. Wainwright
01/25/21 Craig-Hallum
Avadel Pharmaceuticals assumed with a Buy rating at Craig-Hallum
AVDL Avadel Pharmaceuticals
$8.47 /

-1.51 (-15.14%)

AVDL Avadel Pharmaceuticals
$8.47 /

-1.51 (-15.14%)

Initiation
Sage Therapeutics assumed with an Equal Weight at Morgan Stanley » 08:21
10/19/21
10/19
08:21
10/19/21
08:21
SAGE

Sage Therapeutics

$44.05 /

-0.98 (-2.18%)

Morgan Stanley analyst…

Morgan Stanley analyst Vikram Purohit assumed coverage of Sage Therapeutics with an Equal Weight rating with a price target of $66, down from $78. While he believes Zuranolone is a potentially novel treatment option for depression, he suspects the market's views on commercial uptake are "likely to remain constrained due to concerns regarding durability," Purohit tells investors.

ShowHide Related Items >><<
SAGE Sage Therapeutics
$44.05 /

-0.98 (-2.18%)

SAGE Sage Therapeutics
$44.05 /

-0.98 (-2.18%)

10/06/21 Jefferies
Sage Therapeutics downgraded to Hold from Buy at Jefferies
10/06/21 Jefferies
Sage Therapeutics assumed with Hold from Buy at Jefferies
10/04/21 Piper Sandler
Profile of Sage's zuranolone sufficient for NDA filing, says Piper Sandler
09/22/21 Needham
Sage Therapeutics initiated with a Buy at Needham
SAGE Sage Therapeutics
$44.05 /

-0.98 (-2.18%)

SAGE Sage Therapeutics
$44.05 /

-0.98 (-2.18%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.